Found 5 matching trials
Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) NA The purpose of this study is to compare in COPD patients naïve to DPIs, the...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD PHASE1 The purpose of this study is to assess the safety and tolerability of singl...
Show More Location
Quintiles Drug Research Unit at Guy's Hospital
Learn More & Join Trial
Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices PHASE4 The purpose of this study was to compare dynamic inspiratory flow rates ach...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD PHASE4 Rationale:
Inhaled bronchodilators, beta-2-agonist or anticholinergic or c...
Show More Learn More & Join Trial
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects PHASE1 This is a phase I, randomised, placebo-controlled 2-part study to assess th...
Show More Treatments Being Tested
Dose 1, AZD8871 50 μg (Part 1) Dose 2, AZD8871 100 μg (Part 1) Dose 3, AZD8871 300 μg (Part 1) Dose 4, AZD8871 600 µg (Part 1) Dose 5, AZD8871 1200 µg (Part 1) Dose 6, AZD8871 1800 μg (Part 1) Placebo, AZD8871 placebo (Part 1) Treatment A, AZD8871 dose A (Part 2) Treatment B, AZD8871 dose B (Part 2) Treatment C, Indacaterol 150 μg (Part 2) Treatment D, Tiotropium 18 μg (Part 2) Learn More & Join Trial